Patents by Inventor Kevin Hestir

Kevin Hestir has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CSF1R Antibody and Anti-PD-1 Antibody Combination Therapy for Cancer
    Publication number: 20230212299
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Application
    Filed: December 21, 2022
    Publication date: July 6, 2023
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • Combination Anti-CSF1R and Anti-PD-1 Antibody Combination Therapy for Pancreatic Cancer
    Publication number: 20230192870
    Abstract: The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).
    Type: Application
    Filed: July 14, 2022
    Publication date: June 22, 2023
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Katherine E. Lewis, Serena Kimi Perna, Michael Carleton, Ke Xu, Penny Phillips, Dimple Pandya, Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Janine Powers, Ernestine Lee
  • Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers
    Patent number: 11566076
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: January 31, 2023
    Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer
    Patent number: 11421034
    Abstract: The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: August 23, 2022
    Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Katherine E. Lewis, Serena Kimi Perna, Michael Carleton, Ke Xu, Penny Phillips, Dimple Pandya, Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Janine Powers, Ernestine Lee
  • Combination Anti-CSF1R and Anti-PD-1 Antibody Combination Therapy for Pancreatic Cancer
    Publication number: 20210009697
    Abstract: The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).
    Type: Application
    Filed: September 12, 2018
    Publication date: January 14, 2021
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Katherine E. Lewis, Serena Kimi Perna, Michael Carleton, Ke Xu, Penny Phillips, Dimple Pandya, Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Janine Powers, Ernestine Lee
  • Anti-CSF1R Antibody and Anti-PD-1 Antibody Combination Therapy for Cancer
    Publication number: 20200299392
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Application
    Filed: March 4, 2020
    Publication date: September 24, 2020
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer
    Patent number: 10618967
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: April 14, 2020
    Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • Methods of treating lung cancer
    Patent number: 10537611
    Abstract: Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: January 21, 2020
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Harding, Servando Palencia, Li Long, Kevin Hestir
  • Anti-CSF1R Antibody and Anti PD-1 Antibody Combination Therapy for Cancer
    Publication number: 20190202921
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Application
    Filed: January 9, 2019
    Publication date: July 4, 2019
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer
    Patent number: 10221244
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: March 5, 2019
    Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • Methods of Treating Cancer
    Publication number: 20190000920
    Abstract: Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.
    Type: Application
    Filed: June 8, 2018
    Publication date: January 3, 2019
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Thomas Harding, Servando Palencia, Li Long, Kevin Hestir
  • Methods of treating lung cancer
    Patent number: 10016484
    Abstract: Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.
    Type: Grant
    Filed: November 13, 2012
    Date of Patent: July 10, 2018
    Assignee: FIVE PRIME THERAPEUTICS, INC.
    Inventors: Thomas Harding, Servando Palencia, Li Long, Kevin Hestir
  • ANTI-CSF1R ANTIBODY AND ANTI PD-1 ANTIBODY COMBINATION THERAPY FOR CANCER
    Publication number: 20180094067
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Application
    Filed: August 18, 2017
    Publication date: April 5, 2018
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • COMPOSITIONS AND METHODS OF TREATING DISEASE WITH FGFR FUSION PROTEINS
    Publication number: 20170349643
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Application
    Filed: June 12, 2017
    Publication date: December 7, 2017
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen K. Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin G.P. Wong, Ge Wu, Hongbing Zhang
  • Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer
    Patent number: 9765147
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: September 19, 2017
    Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • COMBINATION THERAPY FOR CANCER
    Publication number: 20160152715
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Application
    Filed: October 28, 2015
    Publication date: June 2, 2016
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • COMPOSITIONS AND METHODS OF TREATING DISEASE WITH FGFR FUSION PROTEINS
    Publication number: 20160096876
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Application
    Filed: October 7, 2015
    Publication date: April 7, 2016
    Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen K. Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
  • Methods of treating disease with FGFR1 fusion proteins
    Patent number: 9192683
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: November 24, 2015
    Assignee: FIVE PRIME THERAPEUTICS, INC.
    Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen K. Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
  • FGFR2 fusion proteins comprising C-terminal deletion mutants of FGFR2-IIIC
    Patent number: 9173957
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Grant
    Filed: May 29, 2013
    Date of Patent: November 3, 2015
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen K. Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
  • METHODS OF TREATING CANCER
    Publication number: 20140341900
    Abstract: Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.
    Type: Application
    Filed: November 13, 2012
    Publication date: November 20, 2014
    Inventors: Thomas Harding, Servando Palencia, Li Long, Kevin Hestir